Hepatocellular carcinoma and liver-directed oncology
Clinical activity centres on hepatocellular carcinoma, including non-operable hepatocellular carcinoma and treatment-resistant disease after first-line immunotherapy. The sponsor’s studies reflect interest in liver-focused cancer care, with attention to tumour control in advanced and locally treated liver cancer.
- Selective Internal Radiation Therapy
- Immuno-oncology combinations
- Microbiota and treatment response
Research in this area includes radiopharmaceutical and locoregional therapy strategies alongside systemic approaches for patients with limited surgical options.
Cholangiocarcinoma and biliary tract cancer
The sponsor also studies biliary tract cancer, with particular focus on cholangiocarcinoma in the neoadjuvant setting. This reflects an interest in treatment pathways for resectable disease and in combining local and systemic cancer therapies.
- Intrahepatic cholangiocarcinoma
- Neoadjuvant treatment
- Capecitabine-based combinations
These studies address hepatobiliary oncology with emphasis on patients whose care may involve surgery, liver-directed treatment, and adjunct systemic therapy.
Gastroenteropancreatic neuroendocrine tumors
Research extends to gastroenteropancreatic neuroendocrine tumors, especially well-differentiated disease managed with peptide receptor radionuclide therapy. Imaging-based assessment is a notable interest, supporting evaluation of treatment response and disease evolution.
- ⁶⁸Ga-DOTATATE PET/CT
- ¹⁷⁷Lu-oxodotreotide
- Progression-free survival assessment
The sponsor’s work in this field links molecular imaging with targeted radionuclide treatment in neuroendocrine oncology.
